Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Cytek Biosciences' Cash from Financing Activities rose 11606.26% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year increase of 6550.42%. This contributed to the annual value of -$15.8 million for FY2024, which is 6215.92% up from last year.
  • Cytek Biosciences' Cash from Financing Activities amounted to $1.9 million in Q3 2025, which was up 11606.26% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Cash from Financing Activities peaked at $217.1 million during Q3 2021, and registered a low of -$33.8 million during Q4 2023.
  • Its 5-year average for Cash from Financing Activities is $8.3 million, with a median of $86000.0 in 2021.
  • Per our database at Business Quant, Cytek Biosciences' Cash from Financing Activities soared by 2254705.88% in 2022 and then plummeted by 543806.45% in 2023.
  • Over the past 5 years, Cytek Biosciences' Cash from Financing Activities (Quarter) stood at $17000.0 in 2021, then skyrocketed by 22547.06% to $3.8 million in 2022, then plummeted by 976.73% to -$33.8 million in 2023, then surged by 89.22% to -$3.6 million in 2024, then soared by 153.32% to $1.9 million in 2025.
  • Its Cash from Financing Activities stands at $1.9 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$11.5 million for Q1 2025.